The extra liquidity is one reason for the recovery in the share price, but the settlement of legacy issues has also helped investors mellow towards the company. For example, a dispute over reference prices for Sativex in the key German market, where health insurers were refusing to reimburse the product, was resolved, though GW had to cut the wholesale price for Sativex in return for a new £9.8m 'milestone' payment. This explains the 14 per cent decline in Sativex sales to £2.2m, despite a 51 per cent increase in product shipped.